Khoja Hamid 4

What Happened
Khoja Hamid, Chief Scientific Officer of FibroBiologics (FBLG), was granted an option to purchase 61,607 shares of common stock on May 4, 2026. The grant is reported as a derivative award (Form 4 entry: A) and shows an acquisition amount of 61,607 shares at $0.00 (i.e., an option grant, not an exercised purchase).

Key Details

• Transaction date: 2026-05-04 (filing date: 2026-05-04) — timely filed.
• Transaction type/code: Grant/Award (derivative) — reported as "A".
• Shares/options granted: 61,607 option shares; reported price: $0.00 (option grant, not cash purchase).
• Vesting: 1/4 vests on the one-year anniversary of the grant; remaining balance vests in 36 equal monthly installments thereafter (per footnote F1).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding, cashless exercise, or late reporting in this filing.

Context
This was an equity compensation grant (stock option award), not an open-market buy or sale. Such awards are commonly part of executive compensation and typically vest over time to encourage retention. Because the options were granted (not exercised or sold), there was no immediate cash transaction or disposition of shares reported.